Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cream-and-Steroid combo aims to recolor vitiligo patches

NCT ID NCT07673640

Disease control Sponsor: ShanShan Li Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 29, 2026 · Last updated Sep 09, 2026 · Updated 4 times

Summary

This study tests whether a cream containing ruxolitinib (Opzelura) combined with corticosteroid injections or pills can improve facial vitiligo. It includes people aged 12 and older with active, non-segmental vitiligo affecting the face. Participants use the cream twice daily and take steroids for up to 24 weeks. The main goal is to see how many achieve at least 75% repigmentation of facial patches after 12 weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ruxolitinib phosphate cream (Opzelura) and corticosteroids (betamethasone injection or dexamethasone pills)
What this could lead to
If it works, this combination could offer a more effective way to restore skin color in people with active facial vitiligo.
What could go wrong
This is a real-world study, not a tightly controlled trial, so results may be less clear. Side effects from the cream or steroids are possible, and not everyone may see improvement.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2026

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Males and females aged 12 and older presenting with active, progressive non-segmental vitiligo with facial involvement and a total body surface area (BSA) depigmentation under 10%. Subjects are selected via a non-probability clinical recruitment strategy.

Ages

12 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 12 years at the time of signing informed consent. * Clinical diagnosis of non-segmental vitiligo with facial involvement, and total body surface area (BSA) depigmentation ≤ 10%. * Diagnosed with progressive/active vitiligo meeting at least one of the following: Vitiligo Disease Activity (VIDA) score ≥ 3. Clinical signs including trichrome vitiligo, confetti-like depigmentation, or Koebner phenomenon. The extent of lesions under Wood's lamp is larger than that visible to the naked eye. * Agrees to have no pregnancy plans and uses effective contraception during the study and up to 4 weeks after the last dose. * Voluntarily signs the informed consent form and agrees to regular follow-up visits. Exclusion Criteria: * Diagnosis of other clinical forms of vitiligo (e.g., segmental vitiligo). * Clinically diagnosed with stable vitiligo. * Co-existing skin depigmentation disorders affecting efficacy evaluation (e.g., pityriasis alba, leprosy, post-inflammatory hypopigmentation, progressive macular hypomelanosis, nevus anemicus, chemical leukoderma, tinea versicolor). * Leukoderma lesions with more than 1/3 white hair, or lesions accompanied by white hair where the investigator assesses the probability of benefit from participating is low based on clinical experience. * Contraindications to systemic corticosteroid use. * Known hypersensitivity or allergy to the study medications or excipients. * Known end-stage renal disease (ESRD) or currently undergoing renal replacement therapy (e.g., dialysis). * Concurrent participation in other clinical studies. * Any other condition which, in the investigator's judgment, makes the patient unsuitable for the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-segmental vitiligo (NSV) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

generalized vitiligo vitiligo

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non-segmental vitiligo (NSV)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    20 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Affiliated Hospital of Xuzhou Medical University

    NOT_YET_RECRUITING

    Xuzhou, Jiangsu, China

  • Central Hospital of Jiaozuo Coal Industry (Group) Co., Ltd.

    NOT_YET_RECRUITING

    Jiaozuo, China

  • Changzhi Second People's Hospital

    NOT_YET_RECRUITING

    Shangxi, China

  • Changzhou First People's Hospital

    NOT_YET_RECRUITING

    Changzhou, China

  • Dongying People's Hospital

    RECRUITING

    Dongying, Shandong, China

  • Dongying People's Hospital

    NOT_YET_RECRUITING

    Dongying, China

  • Nanjing Drum Tower Hospital

    NOT_YET_RECRUITING

    Nanjing, China

  • People's Hospital of Ningxia Hui Autonomous Region

    RECRUITING

    Ningxiang, China

  • Shenzhen Hospital of Southern Medical University

    RECRUITING

    Shenzhen, Guangdong, China

  • Shenzhen Hospital, Southern Medical University

    NOT_YET_RECRUITING

    Shenzhen, China

  • Shiyan People's Hospital (Hubei University of Medicine Affiliated People's Hospital)

    NOT_YET_RECRUITING

    Shiyan, China

  • The First Affiliated Hospital of Soochow University

    NOT_YET_RECRUITING

    Suzhou, China

  • The First Affiliated Hospital of Xi'an Jiaotong University

    RECRUITING

    Xi'an, China

  • The First People's Hospital of Lianyungang

    NOT_YET_RECRUITING

    Lianyungang, China

  • The Fourth Affiliated Hospital of Soochow University

    NOT_YET_RECRUITING

    Suzhou, Jiangsu, China

  • The Second Hospital of Lanzhou University

    RECRUITING

    Lanzhou, China

  • The Second People's Hospital of Huai'an

    NOT_YET_RECRUITING

    Huai'an, Jiangsu, China

  • U-Family Clinic (Nanjing) Co., Ltd.

    NOT_YET_RECRUITING

    Nanjing, China

  • Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

    NOT_YET_RECRUITING

    Shanghai, Shanghai Municipality, China

  • Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine

    RECRUITING

    Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.